Therapeutic Drug Monitoring News and Research

RSS

Shifting towards personalized treatment approaches for chronic inflammatory diseases

Chronic inflammatory diseases affect 5% to 7% of the population, regardless of age or sex, from children to the elderly.

6 Nov 2023

BIOHIT HealthCare to host webinar exploring TDM in gastrointestinal medicine

BIOHIT HealthCare is excited to announce its upcoming webinar entitled Proactive vs reactive therapeutic drug monitoring in inflammatory bowel disease (IBD).

From BIOHIT HealthCare Ltd 13 Oct 2023

£5 million awarded to 12 projects aimed at tackling fatal drug overdoses

12 projects awarded a share of £5 million to reduce rates of fatal drug overdoses, as part of Vaccine Taskforce style approach to tackle health challenges.

29 Aug 2023

Real-world management and outcomes of U.S. patients treated with BpaL for rifampin-resistant tuberculosis

Researchers reported on the treatment of rifampin-resistant tuberculosis in the United States using the FDA approved bedaquiline, pretomanid, and linezolid (BPaL) therapy.

1 Jun 2023

Antibody response trajectories among solid organ transplant recipients in association with mycophenolate mofetil administration

Researchers explored the trajectory of antibody (Ab) titers after coronavirus disease 2019 (COVID-19) vaccination among solid organ transplant recipients (SOTs) with or without mycophenolate mofetil (MMF), or withdrawn from MMF.

11 Oct 2022

Higher doses of anti-seizure drugs may be necessary to maintain seizure control in pregnant women

Women taking anti-seizure medications during pregnancy experienced significant decreases in serum concentrations for such drugs during their pregnancy, according to a study published in JAMA Neurology.

31 Mar 2022

Could a fungus-derived compound reduce hyperinflammation in severe COVID-19?

New research from scientists at the University of Pennsylvania, USA, demonstrates that cyclosporine A (CSA), a calcineurin inhibitor that modulates cytokine production, may have potential antiviral properties against coronaviruses.

18 Jun 2021

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.

8 Nov 2020

New antibiotic guidelines could save more lives in intensive care units

More lives could be saved in intensive care units around the world if new antibiotic guidelines designed by The University of Queensland are adopted.

8 May 2020

Bio-Rad publishes new paper on generation, characterization of complex-specific antibodies

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, has published new findings on the generation and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.

From Bio-Rad Laboratories 11 Jan 2019

New therapeutic drug monitoring service could benefit children with cancer

Children with cancer are to benefit nationally from a service which for the first time will allow doctors to personalize their treatment.

28 Nov 2018

Highly sensitive ELISA method for analysis of CET in plasma samples

This article explores the development, full optimization and validation study of a highly sensitive and selective ELISA for determination of cetuximab (CET) in human plasma samples.

23 Feb 2018

Finger prick test offers opportunity to simplify therapeutic drug monitoring of biologics

A new study shows that patients with rheumatoid arthritis and other autoimmune conditions who take the drug adalimumab can monitor drug levels in their bodies with a finger prick rather than undergoing a full blood draw.

9 Aug 2017

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor drug require a change of dose or a switch to a different treatment in the class.

5 Jul 2016

Biomarkers may provide novel approaches to monitoring immunosuppressive therapy in organ transplant patients

Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients--with the potential for individualized therapy to reduce organ rejection and minimize side effects, according to a special article in the April issue of Therapeutic Drug Monitoring, official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

17 Mar 2016

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH).

18 Jan 2016

Cerilliant offers first-ever multi-component solutions for qualitative evaluation of drug interference

Sigma-Aldrich Corporation today announced that the Cerilliant® brand within its Applied Diagnostics and Testing business segment now offers the first-ever reference solutions for qualitative evaluation of drug interferences in a testing laboratory's analytical methods.

15 Sep 2015

Trajan launches prototype blood collection and storage device, hemaPEN

In a world where health care costs are escalating and demands on health care systems are becoming overwhelming, Trajan Scientific and Medical (Trajan) today announces the innovation of hemaPEN, a prototype blood collection and storage device.

4 Sep 2015

Wayne State leads landmark study that examines clinical use of polymyxin B to treat superbugs

With the decline of the development of new antibiotics due to the complexity and expense of discovering them, there has been a rapid growth of antibiotic resistant pathogens that is one of the leading causes of death. With the help of a nearly $4.9 million, 5-year grant from the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, Wayne State University School of Medicine researchers are leading a landmark multi-center, international study that will provide essential information to clinicians for use of polymoxin B in critically ill patients where no other treatments will work.

28 Jul 2015

Landmark study to provide critical information for optimized use of polymyxin B in critically ill patients